Virta Health is proud to announce it was selected as the Spring 2020 recipient of the Employer Health Innovation Roundtable (EHIR) ‘Traction Award,’ recognizing widespread enthusiasm for Virta’s type 2 diabetes reversal offering at the recent EHIR Summit.
EHIR is a group of the world’s most progressive employers, including several Fortune 100 companies, committed to investing in proven solutions to improve the health, wellness, and productivity of their combined 8 million employees and plan members. Twice a year, EHIR hosts an event where emerging healthcare and benefits innovators are invited to present to member companies.
Virta presented at EHIR’s Spring 2020 Summit, showcasing its type 2 diabetes reversal treatment and best-in-class outcomes for A1c reduction, medication de-prescription, and weight loss. Further, Virta shared case studies from customers including US Foods and Purdue University, as well as details on its novel fee-for-outcomes model. Presentations are followed by a match-making process, where EHIR members can choose a company to partner with (or ‘match’) on a pilot program. After matching with the highest number of employers at the event, Virta was honored with the Spring 2020 Traction Award.
“The cost of diabetes management in the U.S. is over $400 billion per year, with employers shouldering a large part of that burden,” said Trent Myers, VP of Sales and Alliances at Virta. “We are thrilled to receive the EHIR Traction Award, a distinction that proves employers are ready to embrace a new paradigm in diabetes care and demand solutions—like Virta—that are proven to deliver better health outcomes, at a lower cost.”
Virta is already working with several EHIR members, including US Foods, Nielsen, and Comcast, to offer its personalized nutrition therapy and provider-led, continuous remote care to their employees. The company is also developing pilot programs with additional EHIR members following the Spring Summit. In partnering with these organizations, Virta can exponentially grow the impact of its solution to reverse type 2 diabetes in America.